All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

A Study Exploring the Cognitive Effects of Risperidone and Aripiprazole in Individuals with Schizophrenia

Author(s): Yiyue Dong, Tianlin Zhang, S. Zhu, Yang Xu and Shaxin Liu*
Department of Rehabilitation Medicine, West China Hospital, 1West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, China

Correspondence Address:
Shaxin Liu, Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China, E-mail: liushaxin@scu.edu.cn


The objective of this study was to analyze the cognitive function and capacity of adult patients with schizophrenia who received treatment with risperidone and aripiprazole. 100 adult patients with schizophrenia, aged 30 y or younger, were enrolled in this study at our hospital's psychiatry department from June 2021 to June 2022. The participants were randomly divided into a control group (n=50) treated with risperidone or an observation group (n=50) treated with risperidone assisted by aripiprazole. The study found that the observation group achieved a higher total effective rate of 90.00 % after 8 w of treatment, which was significantly higher than the 72.00 % rate achieved by the control group (p<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (p>0.05). The scores of the matrics consensus cognitive battery were significantly higher in the observation group (90.15±6.62) than in the control group (80.54±6.75) (p<0.05). Additionally, the observation group showed significantly higher levels of bone metabolic markers, including bone Gla protein, procollagen type I carboxy-terminal propeptide, vitamin D-total and bone-specific alkaline phosphatase, compared to the control group (p<0.05). Moreover, the study showed that the beta-carboxy-terminal telopeptide of type I collagen level was significantly decreased in the observation group compared to the control group (p<0.05). Additionally, according to the study results, activities of daily living scores were significantly higher in the observation group compared to the control group (p<0.05). According to our study, the administration of both risperidone and aripiprazole appears to be an effective way to improve cognitive function, capacity and bone metabolism in adult patients with schizophrenia. The combined treatment provides further therapeutic efficacy without increasing adverse drug reactions, which has important implications for clinical practice.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 61564

Indian Journal of Pharmaceutical Sciences received 61564 citations as per google scholar report